Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,063
  • Shares Outstanding, K 28,682
  • Annual Sales, $ 8,680 K
  • Annual Income, $ -92,840 K
  • 60-Month Beta 2.17
  • Price/Sales 2.18
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VBIV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.10
  • Most Recent Earnings $-0.55 on 05/15/24
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.150 on 12/12/12
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 717.18% ( +489.92%)
  • Historical Volatility 59.86%
  • IV Percentile 91%
  • IV Rank 47.62%
  • IV High 1,437.31% on 04/17/24
  • IV Low 62.53% on 10/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 156
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 17,708
  • Open Int (30-Day) 16,680

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -2.17
  • Growth Rate Est. (year over year) +85.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5712 +4.15%
on 06/20/24
0.8098 -26.54%
on 07/12/24
-0.0005 (-0.08%)
since 06/18/24
3-Month
0.5310 +12.03%
on 04/29/24
0.8098 -26.54%
on 07/12/24
-0.0388 (-6.12%)
since 04/19/24
52-Week
0.4500 +32.20%
on 10/25/23
1.5300 -61.12%
on 07/20/23
-0.9051 (-60.34%)
since 07/19/23

Most Recent Stories

More News
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.5949 (-9.86%)
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.5949 (-9.86%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 10.03 (-1.86%)
VBIV : 0.5949 (-9.86%)
ANTX : 2.79 (-2.11%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 10.03 (-1.86%)
VBIV : 0.5949 (-9.86%)
VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief...

VBIV : 0.5949 (-9.86%)
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts...

VBIV : 0.5949 (-9.86%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 10.03 (-1.86%)
VBIV : 0.5949 (-9.86%)
ANTX : 2.79 (-2.11%)
VBI Vaccines Reports Full Year 2022 Financial Results

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial...

VBIV : 0.5949 (-9.86%)
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President...

VBIV : 0.5949 (-9.86%)
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 2 study...

VBIV : 0.5949 (-9.86%)

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 0.7434
2nd Resistance Point 0.7118
1st Resistance Point 0.6533
Last Price 0.5949
1st Support Level 0.5632
2nd Support Level 0.5316
3rd Support Level 0.4731

See More

52-Week High 1.5300
Fibonacci 61.8% 1.1174
Fibonacci 50% 0.9900
Fibonacci 38.2% 0.8626
Last Price 0.5949
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar